{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:25:15Z","timestamp":1776090315930,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1136\/ijgc-2020-001633","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T10:51:29Z","timestamp":1614077489000},"page":"617-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41\/GEICO 69-O\/ANITA Trial"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct03598270","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antonio","family":"Gonzalez Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Sanchez Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"dePont Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Meirovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Selle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toon","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Marqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001633_bb0010","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001633_bb0015","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine\/carboplatin versus carboplatin in platinum sensitive recurrent ovarian cancer. Results of a gynecologic cancer intergroup randomized phase 111 trial of the ago OVAR, the NCIC CTG and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001633_bb0020","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001633_bb0025","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1002\/cncr.32520","article-title":"Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: still promising?","volume":"125 Suppl 24","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-001633_bb0030","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2020-001633_bb0035","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"Parp inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001633_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2020-001633_bb0045","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2020-001633_bb0050","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2020-001633_bb0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/IGC.0b013e3181d3caa8","article-title":"European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies","volume":"20","author":"Vergote","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001633_bb0060","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001633_bb0065","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001633_bb0070","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001633_bb0075","article-title":"Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III javelin ovarian 200 trial","author":"Pujade-Lauraine","year":"2019","journal-title":"Abstracts Presented for the 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu HI, March 16-19"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:33Z","timestamp":1753233993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24023120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1048891X24023120"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001633","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41\/GEICO 69-O\/ANITA Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}